Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biological functions, has been associated with the progression of various cancers. Using microarrays, we previously identified SPARC as one of the genes induced by treatment with a DNA methylation inhibitor in pancreatic cancer cells. We therefore analysed the expression pattern and methylation status of the SPARC gene in pancreatic cancer. Gene expression profiling by oligonucleotide microarray and reverse transcription-PCR analyses demonstrated that SPARC mRNA was expressed in non-neoplastic pancreatic ductal epithelial cells, but was not expressed in a majority of pancreatic cancer cell lines. The loss of SPARC expression was associated with aberrant hypermethylation of its CpG island. Immunohistochemical labeling revealed that the SPARC protein was overexpressed in the stromal fibroblasts immediately adjacent to the neoplastic epithelium in primary pancreatic cancers, but rarely expressed in the cancers themselves. Primary fibroblasts derived from pancreatic cancer strongly expressed SPARC mRNA and secreted SPARC protein into the conditioned media, and treatment of pancreatic cancer cells with exogenous SPARC resulted in growth suppression. SPARC expression in fibroblasts from noncancerous pancreatic tissue was augmented by coculture with pancreatic cancer cells. These findings suggest that SPARC is a frequent target for aberrant methylation in pancreatic cancer and that SPARC expression in fibroblasts adjacent to pancreatic cancer cells is regulated through tumor-stromal interactions.
Introduction
Infiltrating ductal adenocarcinoma of the pancreas is one of the most aggressive of all of the solid neoplasms, and invasive pancreatic cancer is often associated with a prominent host desmoplastic response. Besides the potential aggressiveness of neoplastic cells themselves, this host response at the site of primary invasion has been considered an important factor in pancreatic cancer progression. Indeed, evidence exists for interactions between pancreatic cancer cells and stromal fibroblasts that affect the invasive phenotype of pancreatic cancer (Maehara et al., 2001) . In contrast to the substantial progress in our understanding of the genetic and epigenetic events that occur within pancreatic cancer cells, molecular mechanisms associated with the tumor-host interactions have not been well characterized. Ryu et al. (2001) used serial analysis of gene expression (SAGE) to compare gene expression profiles of primary carcinomas and passaged cancer cell lines, and identified a cluster of invasion-specific genes. Many of the genes identified were expressed specifically by stromal cells adjacent to the neoplastic epithelium, thus representing potential mediators of the tumor-host interactions (Iacobuzio-Donahue et al., 2002b) .
Secreted protein acidic and rich in cysteine (SPARC)/ osteonectin/BM 40 is a matricellular glycoprotein involved in diverse biological processes, including tissue remodeling, wound repair, morphogenesis, cellular differentiation, cell proliferation, cell migration, and angiogenesis (Jendraschak and Sage, 1996; Yan and Sage, 1999; Bradshaw and Sage, 2001; Brekken and Sage, 2001) . SPARC is highly expressed in a wide range of human malignant neoplasms, and the deregulated expression of SPARC is often correlated with disease progression and/or poor prognosis (Wewer et al., 1988; Bellahcene and Castronovo, 1995; Porte et al., 1995; Porter et al., 1995 Porter et al., , 1998 Ledda et al., 1997; Massi et al., 1999; Rempel et al., 1999; Thomas et al., 2000; Yamanaka et al., 2001) . Interestingly, in certain tumor types, strong expression of SPARC has been detected predominantly in the stroma adjacent to the neoplastic cells (Le Bail et al., 1999; Paley et al., 2000; IacobuzioDonahue et al., 2002a) . These findings have led to the hypothesis that SPARC plays a role in tumor progression at the site of interface between neoplastic cells and the surrounding host cells.
Recently, Yiu et al. (2001) have shown that treatment of ovarian cancer cells with exogenous SPARC inhibits cell proliferation and induces apoptosis. In addition, forced expression of SPARC in ovarian cancer cells resulted in reduced tumorigenicity in nude mice, suggesting that SPARC has a tumor-suppressor function (Mok et al., 1996) . In addition to its effects on cellular proliferation, SPARC has been linked with tumor invasion. SPARC has been shown to increase the invasive capacity of prostate and breast cancer cells in vitro (Jacob et al., 1999; Briggs et al., 2002) and promote invasion of glioma in vivo (Schultz et al., 2002) . Thus, the biological functions of SPARC appear to be variable among cancer types, and it is not known whether this protein is involved in pancreatic cancer progression.
DNA methylation is a major mechanism associated with the inactivation of tumor-suppressor genes in cancer (Jones and Baylin, 2002) . We have previously reported that many benign and malignant pancreatic neoplasms harbor methylation abnormalities including aberrant hypermethylation of genes such as p16, preproenkephalin, TSLC1 and others (Ueki et al., 2000 (Ueki et al., , 2001 Fukushima et al., 2002; Jansen et al., 2002; Sato et al., 2002; Matsubayashi et al., 2003) and aberrant hypomethylation of S100A4 and others (Rosty et al., 2002b; Sato et al., 2003b) . In an attempt to discover additional genes targeted for aberrant methylation in pancreatic cancer, we have used oligonucleotide microarrays to screen for genes that are induced by treatment with the demethylating agent 5-aza-2 0 -deoxycytidine (5Aza-dC) in pancreatic cancer cell lines (Sato et al., 2003a) . One of the genes identified was SPARC, suggesting that this gene can be regulated by DNA methylation.
The purpose of this study was to characterize the expression pattern of SPARC in pancreatic adenocarcinoma, to determine the role of DNA methylation in the expression of SPARC in pancreatic tissues, and to elucidate the role of SPARC in pancreatic cancer progression, with a focus on the tumor-stromal interactions.
Materials and methods

Materials
A monoclonal anti-SPARC antibody (clone ON1-1) was purchased from Zymed Laboratories, Inc. (South San Francisco, CA, USA). 5Aza-dC was purchased from Sigma Chemical Co. (St Louis, MO, USA). Purified human platelet SPARC protein was purchased from Calbiochem (Cambridge, MA, USA).
Cell lines and tissue samples
In total, 17 human pancreatic cancer cell lines (AsPC1, BxPC3, Capan1, Capan2, CFPAC1, Colo357, Hs766T, MiaPaCa2, Panc1, PL1, PL3, PL6, PL9, PL10, PL11, PL12, and PL13) were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), streptomycin, and penicillin at 371C in a humidified atmosphere containing 5% CO 2 . An immortal cell line derived from normal human pancreatic ductal epithelium (HPDE) was generously provided by Dr Ming-Sound Tsao (University of Toronto, Ontario, Canada) and maintained in Keratinocyte-SFM (Invitrogen). Primary fibroblasts were initially outgrown from chronic pancreatitis tissue from a 33-year-old male patient (panc-f1), from noncancerous pancreatic tissue from a 61-year-old female patient with pancreatic cancer (panc-f3), or from pancreatic adenocarcinoma tissue from a 55-year-old female patient (panc-f5). These fibroblast cultures were carefully evaluated by light microscopy to exclude epithelial cell contamination, maintained in RPMI 1640 with 10% FBS, and used at 5-10 passages. Formalin-fixed paraffin-embedded blocks of 25 primary pancreatic adenocarcinomas resected at The Johns Hopkins Hospital were selected on the basis of tissue availability. Pancreatic cancer xenografts were established from surgically resected primary pancreatic carcinomas (Hahn et al., 1995) , and 24 xenografts were randomly selected for this study. Normal pancreatic duct epithelial cells were selectively microdissected from resected pancreata from 10 patients (mean age, 64.3 years; range, 36-83) with pancreatic ductal adenocarcinoma (eight patients), chronic pancreatitis (one patient), or islet cell tumor (one patient) using a lasercapture microdissection (LCM) system. Serum samples were collected from 20 patients with pancreatic adenocarcinoma, 20 patients with benign pancreatic disorders, and 20 healthy individuals.
Oligonucleotide array hybridization and data analysis
Total RNA was isolated from cultured cells or frozen tissues using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). First-and second-stranded cDNA was synthesized from 10 mg of total RNA using T7-(dT) 24 primer (Genset Corp., South La Jolla, CA, USA) and SuperScript Choice system (Invitrogen). Labeled cRNA was synthesized from the purified cDNA by in vitro transcription (IVT) reaction using the BioArray HighYield RNA Transcript Labeling Kit (Enzo Diagnostics, Inc., Farmingdale, NY, USA) at 371C for 6 h, and was purified using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The cRNA was fragmented at 941C for 35 min in a fragmentation buffer (40 mmol/l Tris-acetate (pH 8.1), 100 mmol/l potassium acetate, 30 mmol/l magnesium acetate). The fragmented cRNA was then hybridized to the Human Genome U133A chips (Affymetrix, Santa Clara, CA, USA) with 18 462 unique gene/ EST transcripts at 451C for 16 h. The washing and staining procedure was performed in the Affymetrix Fluidics Station according to the manufacturer's instructions. The probes were then scanned using a laser scanner, and signal intensity for each transcript (background-subtracted and adjusted for noise) and detection call (present, absent, or marginal) were determined using Microarray Suite Software 5.0 (Affymetrix).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA (4 mg) was reverse-transcribed using Superscript II (Invitrogen). The SPARC reverse transcription-polymerase chain reaction (RT-PCR) reaction was performed under the following conditions: 951C for 5 min; then 28 cycles of 951C for 20 s, 631C for 20 s, and 721C for 20 s; and a final extension of 4 min at 721C. Primer sequences were 5 0 -AAG ATC CAT GAG AAT GAG AAG-3 0 (forward) and 5 0 -AAA AGC GGG TGG TGC AAT G-3 0 (reverse). To check the integrity of mRNA, glyceraldehyde-3-phosphate dehydrogenase Aberrant methylation of SPARC in pancreatic cancer N Sato et al (GAPDH) was also amplified in the same PCR condition. For semiquantitative analysis, the RT-PCR was performed with primers for SPARC and GAPDH in duplex reactions, and the range of linear amplification for both genes was examined with serial PCR cycles to determine the optimal cycle. The relative intensity of SPARC mRNA expression was then corrected for variable RNA recovery using the corresponding GAPDH mRNA measurement as a surrogate for total mRNA.
Immunohistochemistry
Sections (5 mm) were cut onto coated slides and deparaffinized by routine techniques. Antigen retrieval was performed in 10 mm sodium citrate buffer (pH 6.0), heated at 951C in a steamer for 20 min. After blocking endogenous peroxidase activity with a 3% aqueous H 2 O 2 solution for 5 min, the sections were incubated with an anti-SPARC monoclonal antibody at a final concentration of 4 mg/ml for 60 min. Labeling was detected with the Envision Plus Detection Kit (DAKO, Carpinteria, CA, USA), following the protocol as suggested by the manufacturer, and all sections were counterstained with hematoxylin. The extent of immunolabeling of SPARC was categorized into three groups: 0%, negative; ¼ or o10%, focal; and 410%, positive. The intensity of immunolabeling was categorized as
Bisulfite treatment of genomic DNA and sequencing analysis
Genomic DNA was isolated from the cell lines, frozen tissues, and xenografted tumors using a DNA isolation kit (Qiagen, Valencia, CA, USA), and subjected to sodium bisulfite treatment as described previously (Herman et al., 1996) . A 221-bp fragment of the 5 0 region of the SPARC gene was amplified using the primers: ATT TAG TTT AGA GTT TTG AGT GG (forward) and ACA AAA CTT CCC TCC CTT AC (reverse). PCR conditions were as follows: 951C for 5 min; 40 cycles of 951C for 20 s, 601C for 20 s, and 721C for 30 s; and a final extension of 4 min at 721C. After incubation with exonuclease I and shrimp alkaline phosphatase (USB, Cleveland, OH, USA), the PCR products were sequenced using the SequiTherm Excel II cycle sequencing kit, as recommended by the manufacturer (Epicentre Technologies, Madison, WI, USA). Products of the sequencing reactions were resolved by electrophoresis and visualized by autoradiography. The methylation status of each sample was evaluated by determining the percentage of the intensity of the cytosine band vs the thymine band for each CpG site.
Methylation-specific polymerase chain reaction (MSP)
Methylation status of the SPARC gene was also determined by MSP as described previously (Herman et al., 1996) . Bisulfitetreated DNA (1 mg) was amplified using primers specific for either the methylated or the unmethylated DNA under the conditions as follows: 951C for 5 min; 40 cycles of 951C for 20 s, 621C for 20 s, and 721C for 30 s; and a final extension of 4 min at 721C. Primer sequences were TTT TTT AGA TTG TTT GGA GAG TG (forward) and AAC TAA CAA CAT AAA CAA AAA TAT C (reverse) for unmethylated reactions (132 bp), and GAG AGC GCG TTT TGT TTG TC (forward) and AAC GAC GTA AAC GAA AAT ATC G (reverse) for methylated reactions (112 bp). Each PCR product (5 ml) was loaded onto 3% agarose gels and visualized by ethidium bromide staining.
5Aza-dC treatment
We treated eight pancreatic cancer cell lines (AsPC1, BxPC3, Capan2, CFPAC1, Hs766T, MiaPaCa2, PL3, and PL12) with 5Aza-dC. Cells in log phase growth were seeded in T-75 culture flasks. After overnight incubation, the cells were exposed continuously to 5Aza-dC (1 mm) for 4 days, with a change of drug and culture medium every 24 h.
SPARC enzyme-linked immunosorbent assay (ELISA)
Cells were seeded at a density of 1 Â 10 5 cells/well in six-well plates. After overnight incubation, the cells were washed with phosphate-buffered saline (PBS) and incubated in 2 ml of serum-free medium for 24 h. The conditioned media were harvested and centrifuged to remove cellular debris. SPARC concentration in the conditioned media was measured using an enzyme-linked immunosorbent assay (ELISA) kit (Haematological Technologies, Inc., Essex Junction, VT, USA), according to the manufacturer's instructions. SPARC levels were measured in the serum samples in a similar fashion.
Treatment of pancreatic cancer cells with SPARC
We treated two pancreatic cancer cell lines (AsPC1 and Panc1) with exogenous SPARC. Cells in log phase growth were seeded at a density of 1 Â 10 4 cells/well in 24-well plates. After overnight incubation, cells were treated with or without human platelet SPARC protein (10 mg/ml) for 72 h, and the number of cells was counted by a hemacytometer in three independent wells.
Fibroblasts/pancreatic cancer cells coculture
Fibroblasts were seeded in six-well plates and grown for 48-72 h. Pancreatic cancer cells (CFPAC1) were then seeded into the upper chamber of a transwell apparatus (Becton Dickinson, Franklin Lakes, NJ, USA), which physically separated the tumor cells from the fibroblasts but allowed for interaction between the cells via soluble factors. After 48-h incubation, fibroblasts were washed with PBS and harvested by trypsinization.
Statistical analysis
Statistical analysis was performed using Fisher's exact probability test or unpaired Student's t-test (two-tailed). Differences were considered significant at Po0.05.
Results
Gene expression analysis of SPARC in pancreatic cancer by SAGE and oligonucleotide microarrays
We previously used oligonucleotide microarrays to identify genes that are induced fivefold or greater by treatment of pancreatic cancer cells with 5Aza-dC (Sato et al., 2003a) . SPARC was one of the genes we identified using this approach. We therefore analysed the gene expression and methylation status of the SPARC gene in pancreatic cancer. First, we searched an online SAGE database (http://www.ncbi.nlm.nih.gov/SAGE/) to determine the gene expression patterns of SPARC in short-term cultures of normal pancreatic ductal epithelium, pancreatic cancer cell lines, and primary pancreatic cancer tissues. The SAGE Tag to Gene Mapping Aberrant methylation of SPARC in pancreatic cancer N Sato et al analysis showed that the Hs.111779 tag (ATGTGAA-GAG) corresponding to the SPARC gene was present in both of two libraries from normal pancreatic duct epithelial cell cultures (H126 and HX), whereas the SPARC tag was not identified in three of four pancreatic cancer cell lines (Figure 1a) . By contrast, the SPARC tag was detected at high levels in two primary pancreatic adenocarcinoma tissues (Panc 91-16113 and Panc 96-6252) , suggesting that this gene may be an 'invasionspecific gene', a gene whose expression is specifically identified in tissue specimens of invasive pancreatic cancer, but not in passaged pancreatic cancer cell lines (Ryu et al., 2001) .
We then determined SPARC expression by analysing global gene expression profiling (U133A oligonucleotide microarrays, Affymetrix) in two frozen tissue samples of normal pancreatic ductal epithelial cells selectively microdissected by LCM, a non-neoplastic pancreatic epithelial cell line (HPDE), and five pancreatic cancer cell lines (AsPC1, CFPAC1, Hs766T, MiaPaCa2, and Panc1). The SPARC transcript was detected in the normal pancreatic ductal epithelial cells and HPDE (Figure 1b) . In contrast, SPARC was not expressed in four of the five pancreatic cancer cell lines.
Expression of SPARC mRNA in pancreatic cancer cell lines and primary fibroblasts
We next performed RT-PCR to examine the expression of SPARC mRNA in a panel of 17 pancreatic cancer cell lines and in primary fibroblast cultures derived from chronic pancreatitis tissue (panc-f1) and from pancreatic adenocarcinoma tissue (panc-f5). The SPARC transcript was detectable in a non-neoplastic pancreatic ductal epithelial cell line (HPDE) and was moderately (in pancf1) to strongly (in panc-f5) expressed in these fibroblasts, whereas the expression was absent in 15 (88%) of the 17 pancreatic cancer cell lines (Figure 1c ). Of note, the RT-PCR results of seven pancreatic cancer cell lines (AsPC1, Capan1, Capan2, CFPAC1, Hs766 T, MiaPaCa2, and Panc1) parallel the SAGE and/or oligonucleotide array data on these same cell lines. These results demonstrate the striking difference in SPARC expression between most pancreatic cancer cell lines and stromal fibroblasts.
Immunohistochemical analysis of SPARC expression in pancreatic carcinoma
The expression of SPARC protein was examined in 25 primary pancreatic adenocarcinoma tissues (of which 14 cases contained normal ducts) by immunohistochemical labeling with an anti-SPARC monoclonal antibody. In 19 (76%) of 25 cases, moderate ( þ þ ) to strong ( þ þ þ ) SPARC expression was found in the stromal cells, presumably fibroblasts, and positive immunolabeling was identified as dark brown granules throughout the cytoplasm (Figure 2 ). In these cases, the expression was most pronounced in the peritumoral stroma (which was defined as a 10-cell stromal layer surrounding the , whereas the staining was weak or absent in the stroma distant from the infiltrating carcinoma. Immunolabeling of SPARC was also observed in neoplastic epithelium in eight (32%) of 25 cases, but the labeling was weak and focal, with the exception of a single case in which 50% of the neoplastic cells were strongly labeled. In the remaining 17 cases (68%), neoplastic cells did not label for SPARC throughout the tumor (Figure 2 ). Normal ductal epithelial cells showed weak cytoplasmic staining in 11 (79%) of 14 cases, but did not label in the remaining three cases. These immunohistochemical findings suggest that the increased SPARC tags detected in the SAGE libraries of the primary pancreatic cancer tissues originated primarily from stromal fibroblasts.
Methylation analysis of SPARC gene in pancreatic cancer
We next analysed the methylation status of the SPARC gene in pancreatic cancer and normal pancreatic tissue. SPARC has a relatively CpG-rich sequence spanning from exon 1 to intron 1 (GC content of 64%, ratio of CpG to GpC of 0.6, and a length of 279 bp), which fulfills the criteria of the CpG island (Figure 3a) . To evaluate the methylation status of the SPARC gene, bisulfite genomic sequencing was performed on its 5 0 region, including 12 CpG dinucleotides within the CpG island ( Figure 3a ) in eight pancreatic cancer cell lines and non-neoplastic HPDE. We found that HPDE was unmethylated at all the 12 CpG sites (Figure 3b) . By contrast, all the CpG sites tested were completely (100%) methylated in five pancreatic cancer cell lines (AsPC1, Capan2, CFPAC1, Colo357, and MiaPaCa2; Figure 3b ) and partially (50-70%) methylated in one cell line (Panc1). Two pancreatic cancer cell lines (BxPC3 and PL12) were unmethylated at two CpG sites (at positions of þ 9 and þ 11), but almost completely (490%) methylated at other downstream CpGs.
We also examined the methylation status of the SPARC gene in a larger panel of pancreatic cancer cell lines by MSP. Primers for MSP were designed to detect methylation of several CpGs demonstrated by bisulfite sequencing (Figure 3a) , and concordant results were obtained for all cell lines analysed by both bisulfite sequencing and MSP (not shown). Overall, the SPARC CpG island was unmethylated in HPDE and primary fibroblasts (panc-f5), but was aberrantly methylated in 16 (94%) of the 17 pancreatic cancer cell lines as shown by MSP (Figure 3c) . Importantly, the methylation status of SPARC correlated with its expression; the mRNA expression of SPARC was lost in 15 (94%) of the 16 cell lines with methylated SPARC and was retained in the remaining one (Panc1), where the SPARC CpG island was hemi-methylated. By contrast, the SPARC transcript was present in HPDE, primary fibroblasts (pancf5), and a pancreatic cancer cell line (PL9) with unmethylated SPARC (P ¼ 0.004, Fisher's test).
To confirm that DNA methylation is a mechanism for the silencing of SPARC, we treated eight pancreatic cancer cell lines harboring SPARC methylation with the demethylating agent 5Aza-dC. The SPARC mRNA expression was restored in seven of the eight cell lines after 5Aza-dC treatment (Figure 3d ). In one cell line (Hs766T), however, 5Aza-dC treatment did not restore the SPARC expression. Furthermore, treatment of Hs766T with the histone deacetylase inhibitor trichostatin A (TSA) or with a combination of 5Aza-dC and TSA did not induce SPARC expression (data not shown). These results suggest that mechanisms other than DNA methylation and histone deacetylation may be involved in the silencing of SPARC in this cell line.
We also analysed the methylation status of SPARC in a panel of 24 xenograft tumors established from human primary pancreatic carcinomas and compared it to methylation patterns in 10 normal pancreatic ductal epithelia selectively microdissected by LCM. Aberrant methylation of SPARC was detected in 21 (88%) of the 24 pancreatic xenografts (Figure 3e ), whereas none of the 10 normal ductal epithelium samples displayed methylated alleles (Figure 3f ). These results confirm the abnormal methylation pattern of SPARC in primary pancreatic carcinomas as well as in pancreatic cancer cell lines.
Effect of SPARC on proliferation of pancreatic cancer cells
Since SPARC is a secreted protein and has multiple biological functions, the altered patterns of SPARC expression in pancreatic cancer cells and stromal fibroblasts could affect tumor progression at the site of tumor-host interface. Based on the expression data, we hypothesized that SPARC protein is secreted from stromal fibroblasts within invasive pancreatic carcinoma. To test this hypothesis, we measured the SPARC concentration in conditioned media from three pancreatic cancer cell lines (AsPC1, BxPC3, and Panc1) and fibroblasts derived from pancreatic cancer (panc-f5) by ELISA. The amount of SPARC secretion was negligible Figure 2 Immunohistochemical staining for SPARC in pancreatic adenocarcinoma. Strong cytoplasmic labeling is detected in the stromal fibroblasts, in contrast to the neoplastic epithelium that is negative for SPARC. Original magnification, Â 160
Aberrant methylation of SPARC in pancreatic cancer N Sato et al (0-30 ng/ml) in media from AsPC1 and BxPC3 with no detectable mRNA expression, and a slightly higher secretion of SPARC protein (B100 ng/ml) was found in Panc1 with detectable mRNA expression. The highest SPARC secretion (B1400 ng/ml) was identified in the fibroblast cultures. These results demonstrate a correlation between SPARC mRNA expression and the amount of SPARC secretion in vitro.
We then evaluated the effect of exogenous SPARC protein on growth of pancreatic cancer cells in vitro. (Figure 4) . Thus, these results suggest that exogenous SPARC protein has growth-suppressive activity on pancreatic cancer cells.
Serum SPARC levels in patients with pancreatic disease
We measured the concentration of SPARC protein in serum samples from 20 patients with pancreatic adenocarcinoma, 20 patients with benign pancreatic disorders, and 20 healthy individuals by ELISA. There was no significant difference in the mean SPARC levels among these three groups (data not shown).
Effects of tumor-stromal interactions on SPARC expression in fibroblasts
To elucidate the relationship between tumor-host interactions and transcriptional regulation of SPARC in stromal fibroblasts, we compared the SPARC mRNA expression in three primary fibroblast cultures derived from different histological types of pancreatic tissues. Using semiquantitative RT-PCR, we found that fibroblasts derived from chronic pancreatitis tissue (panc-f1) and those from noncancerous pancreatic tissue from a patient with pancreatic cancer (panc-f3) showed weaker expression of SPARC mRNA compared to fibroblasts derived from pancreatic cancer tissue (panc-f5) (Figure 5a ). These results, together with the immunohistochemical finding of SPARC expression localized to the peritumoral stroma, have led us to hypothesize that SPARC expression in the stromal fibroblasts is modulated by interactions with tumor cells. To test this hypothesis directly, we utilized a coculture system in which fibroblasts (panc-f3) and pancreatic cancer cells (CFPAC1) can communicate via soluble factors. SPARC mRNA expression in panc-f3 was markedly (B4.6-fold) augmented when these cells were cocultured with pancreatic cancer cells (Figure 5b) . Thus, the SPARC transcription in the fibroblasts can be upregulated in response to soluble mediators secreted by pancreatic cancer cells.
Discussion
In order to obtain insights into the role of SPARC in the progression of pancreatic cancer, we investigated the role of DNA methylation in the expression of SPARC in pancreatic cancer cells and stromal fibroblasts. Our results show that (i) SPARC expression is frequently lost in pancreatic cancer cells in conjunction with aberrant DNA methylation, (ii) SPARC is highly expressed by peritumoral fibroblasts, (iii) SPARC expression in fibroblasts is enhanced by coculture with pancreatic cancer cells, and (iv) exogenous SPARC inhibits the growth of pancreatic cancer cells in vitro. These results suggest that SPARC plays an important role in tumorhost interactions between pancreatic cancer cells and stromal fibroblasts. Despite the important nature of SPARC in diverse biological processes, little is known about the transcriptional regulation of SPARC. Here we provide evidence that SPARC is transcriptionally regulated by DNA methylation. In the vast majority of pancreatic cancer cell lines, SPARC was found to be silenced in association with aberrant methylation of its 5 0 CpG island, and treatment of these cell lines harboring methylated SPARC with 5Aza-dC restored its expression. Aberrant methylation of SPARC was also detected at a high frequency (B90%) in xenografted primary pancreatic carcinomas, which supports our previous study describing a concordance of abnormal methylation patterns at multiple loci between pancreatic cancer cell lines and primary pancreatic cancers . The SPARC gene is located at chromosome 5q31.3-q32, and loss of heterozygosity (LOH) at 5q has been detected in B20% of pancreatic cancers (Hahn , 1995) . Thus, our findings raise the possibility of two-hit inactivation of the SPARC gene by LOH and hypermethylation in a subset of pancreatic cancers. Based on previous studies showing that primary cultures from SPARC-null mice have increased proliferation rates and that inducible expression of SPARC in human breast cancer cells results in growth inhibition (Dhanesuan et al., 2002) , we hypothesize that epigenetic inactivation of SPARC by aberrant methylation provides a growth advantage to pancreatic cancer cells, thereby contributing to pancreatic neoplastic progression.
In this study, we were not able to detect SPARC expression in some normal pancreatic ductal epithelial cells by immunohistochemistry, although the SPARC transcript was present in normal ductal epithelial cells and a non-neoplastic ductal cell line, as evidenced by SAGE and microarray analyses. One possible explanation for this discrepancy may relate to the limited sensitivity of our immunohistochemical assay to detect faint expression of SPARC in archival tissue sections, or it could also be that expression of SPARC varies with cell cycle. It is also possible that aberrant methylation and inactivation of SPARC gene may be an early event involving pathologically normal-appearing ductal epithelium in patients with pancreatic cancer. However, the latter is unlikely because, in our present analysis, aberrant methylation of SPARC was not detected in a panel of 10 normal ductal epithelium samples.
Our results also provide evidence that SPARC expression in stromal fibroblasts is enhanced through their interactions with tumor cells. By coculturing CFPAC1 pancreatic cancer cells and fibroblasts, we found that SPARC mRNA expression in fibroblasts is markedly augmented as a result of soluble factors released from pancreatic cancer cells. The tumor-derived mediator(s) that stimulate(s) the transcription of SPARC in stromal fibroblasts is presently unknown, but these results concur with the immunohistochemical finding of SPARC expression localized to the stroma immediately adjacent to the invasive pancreatic carcinoma. Although CFPAC1 is a representative pancreatic cancer cell line characterized by typical genetic alterations (Kern, 2000) and by a characteristic gene expression profile similar to those of many other pancreatic cancer cell lines (Iacobuzio-Donahue et al., 2003) , additional coculture experiments using different pancreatic cancer cell lines as well as different fibroblast cultures will be required to the generalizability of our findings to other pancreatic cancers.
As SPARC is a multifunctional protein involved in cell proliferation, cell spreading, adhesion, motility, and invasion (Jendraschak and Sage, 1996; Yan and Sage, 1999; Bradshaw and Sage, 2001; Brekken and Sage, 2001) , the fibroblast-derived SPARC may have diverse effects on the biology of pancreatic cancer cells. Evidence linking stromal SPARC and tumor progression comes from a recent study demonstrating that growth of implanted tumors is enhanced in mice lacking endogenous SPARC (Brekken et al., 2003) . In the present study, we found that exogenous SPARC protein suppressed the growth of pancreatic cancer cells in vitro. These results suggest that although pancreatic cancer cells frequently lose SPARC expression, SPARC released from peritumoral fibroblasts in vivo may inhibit the growth of pancreatic cancer cells. SPARC may thus represent one of the mediators of tumor-stromal interactions that individually act to facilitate or retard tumor progression. Consistent with our results, Yiu et al. (2001) demonstrated that exogenous SPARC inhibits cell proliferation and induces apoptosis in ovarian cancer cells. Interestingly, the authors also showed evidence that putative SPARC receptors are present on ovarian epithelial cells, suggesting that binding of SPARC to its receptor may trigger tissue-specific signaling pathways that mediate its tumor-suppressing functions (Yiu et al., 2001) . Although the exact mechanism by which SPARC inhibits cellular proliferation is unknown, previous studies have shown that SPARC inhibits DNA synthesis and arrests cells in the G1 phase of the cell cycle Sage, 1991, 1993) . Primary mesangial cells isolated from SPARC-null mice showed an increased proliferation rate in association with an increase in the cell cycle regulatory protein cyclin A and an increased activity of the insulin-like growth factor signaling pathway (Francki et al., 2003) . Furthermore, SPARC has been shown to stimulate production of TGF-b in mesangial cells . These findings suggest that modulation of cell cycle regulatory proteins and/or growth factors may account, at least in part, for the antiproliferative function of SPARC. In addition to its effects on cell proliferation, SPARC is known to affect the invasive phenotype of certain tumor cells. For example, SPARC has been shown to increase the invasive capacity of prostate and breast cancer cells through enhancing matrix metalloproteinase activity (Jacob et al., 1999) . Increased motility and invasion in MCF7 breast cancer cells transfected with c-Jun protooncogene is associated with induction of SPARC expression (Briggs et al., 2002) . Recently, Schultz et al. (2002) demonstrated that SPARC delays tumor growth but promotes invasion of glioma in vivo. SPARC is also known to regulate the activity of growth factors involved in angiogenesis, such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF)-2, and vascular endothelial growth factor (VEGF) (Jendraschak and Sage, 1996; Brekken and Sage, 2001) . Additional studies are needed to evaluate the exact biological effects of fibroblast-secreted SPARC protein on pancreatic cancer progression.
Our present findings may suggest possible clinical applications. First, because SPARC is frequently methylated in pancreatic cancers and not, at least in part, in our panel of normal ductal epithelium samples tested, it might be a useful strategy for diagnosing pancreatic cancer to detect aberrantly methylated SPARC by MSP in pancreatic juice Sato et al., 2003a) . Since pancreatic cancer is often diagnosed late in its natural history and since serum markers are not sufficiently sensitive or specific, several investigators have applied markers to pancreatic juice as an approach to improve the diagnosis of pancreatic cancer Rosty and Goggins, 2002; Rosty et al., 2002a) . Second, because our preliminary data showed that SPARC has antiproliferative activity on pancreatic cancer cells, the functional restoration of SPARC in pancreatic cancer can be a novel therapeutic strategy against this aggressive neoplasm, as has been previously demonstrated in ovarian and breast cancer (Mok et al., 1996; Dhanesuan et al., 2002) .
In summary, we have identified SPARC as a frequent target for aberrant methylation in pancreatic cancer. We also provide evidence that SPARC is a potential mediator of tumor-host interactions between pancreatic cancer cells and stromal fibroblasts.
Abbreviations SAGE, serial analysis of gene expression; 5Aza-dC, 5-aza-2 0 -deoxycytidine; RT-PCR, reverse transcription-polymerase chain reaction; MSP, methylation-specific polymerase chain reaction.
